

# THE DOSE

## Insights and Updates from Cigna Pharmacy



JUNE 2019

[VIEW ONLINE](#)

### Accredo to be Cigna's preferred specialty pharmacy

As a premier specialty pharmacy, and part of the Express Scripts portfolio of services, Accredo will be Cigna's preferred specialty pharmacy starting later this year. This means that customers who use Cigna Specialty Pharmacy today will receive their specialty pharmacy services from Accredo, a Cigna company.<sup>1</sup> Cigna's current in-house specialty pharmacy will be integrated into Accredo.

Accredo is a leading specialty pharmacy with more than 35 years' experience in specialty pharmacy operations, condition-specific clinical programs and most importantly, compassionate customer care.

**Accredo will help Cigna lead the way in three key areas that are essential to improving customer health and lowering overall costs:**

1. **Clinical capabilities and individualized focused care to drive improved outcomes** (500 condition-focused pharmacists and over 350 proprietary clinical protocols)<sup>2</sup>
2. **Local and community support to drive better health and care engagement** (200 nurse educators helping caregivers, 200 trusted physician advisors and 550 home infusion nurses across the United States)<sup>2</sup>
3. **Scale and integration to drive savings**

[Read more](#) about how Cigna Pharmacy Management and Accredo are dedicated to specialty drug management and clinical care.

1. Some specialty medications carried at Cigna are not carried at Accredo. Cigna Specialty Pharmacy will continue to fill these medications. This process is subject to change.

2. Accredo team of health care professionals as of May 2019. This information is subject to change.

### Cigna Pharmacy Management\*

We are a Pharmacy Benefits Manager within a global health service company. Our goal is to leverage holistic customer insights and integrated analytics to deliver a more personalized experience and, ultimately, better outcomes and lower total medical costs.

### What's inside?

Accredo to be Cigna's preferred specialty pharmacy .....	1
Reducing medication cost surprises .....	2
Therapeutic Resource Centers .....	2
Freedom Fertility Pharmacy .....	3
Cigna Collaborative Care .....	3

### Drug updates

Pipeline review .....	4
Formulary updates .....	5
Brand drug additions .....	6
Generic drug additions .....	7
Tier changes .....	8
On the horizon .....	10

Together, all the way.®





## Helping to reduce surprise medication costs for our customers

Cigna is committed to helping our customers stay healthy and reduce their health care costs. One of the many ways we achieve our goals is by delivering innovative digital tools and resources for our customers. That's why we've built the new Price a Medication feature on the myCigna® App. This tool gives customers the ability to price and compare their medications across in-network pharmacies, including Cigna Home Delivery Pharmacy<sup>SM</sup>.<sup>\*</sup> We're also encouraging customers to use the tool right from their health care provider's office. This can help providers identify potential lower-cost alternatives, and eliminate surprise expenses for customers at the pharmacy.

The Price a Medication feature on the myCigna App gives customers the ability to:

- > Compare prices across in-network pharmacies in the area, as well as Cigna Home Delivery Pharmacy<sup>\*</sup>
- > View costs for 30-day and 90-day supplies, depending on what a customer's plan covers
- > Find out right away if a medication needs approval before the plan will cover it
- > Receive alerts if their plan doesn't cover a medication and provide covered alternatives, if available
- > See medication prices in a simple map view, with directions to the pharmacy if needed

The myCigna App is available for Cigna customers on Apple® and Android™ devices.<sup>\*\*</sup>

Apple is a registered trademark of Apple Inc. Android is a trademark of Google LLC.

<sup>\*</sup> Prices are not guaranteed and pricing at individual pharmacies may vary. Not all plans include Cigna Home Delivery Pharmacy. Review your plan documents for cost and coverage details. The display of a price is not a guarantee of coverage. Your costs and coverage may be different when you fill your prescription at the pharmacy. Pricing at individual pharmacies may vary. Your pharmacy may offer a special sale price on a specific medication which may be less than the price on the Drug Cost Tool. Please consult your pharmacy.

<sup>\*\*</sup> The downloading and use of the myCigna App is subject to the terms and conditions of the App and the online store from which it is downloaded. Standard mobile phone carrier and data usage charges apply.

## Therapeutic Resource Centers<sup>SM</sup> offer highly focused individual support

Those taking a specialty medication and living with challenging health conditions deserve personalized guidance and support. They need a trained clinician to lean on, who thoroughly understands their condition and medication. Customers with complex conditions who take a specialty medication dispensed by Accredo, a Cigna specialty pharmacy, benefit from specialty medication and condition counseling through Accredo's Therapeutic Resource Centers (TRCs). Customers receive one-on-one, condition-focused care from specialty-trained pharmacists and nurses.

As part of Cigna's combination with Express Scripts, our current in-house specialty pharmacy will integrate into Accredo. This means that Cigna customers will benefit from the specialty condition counseling of the TRCs in the future.

There are currently 15 TRCs<sup>\*</sup>, each highly focused to support an individual therapy class, like oncology, fertility or immune disorders.

Cigna customers who manage the challenges of a complex condition do not face it alone. Customers taking a specialty medication not dispensed by Accredo will receive this important specialty medication and condition counseling from Cigna specialty condition clinicians.

[Learn More.](#)

<sup>\*</sup>[Express Scripts Therapeutic Resource Centers](#) include Asthma, Allergies, Cancer, Diabetes, Hemophilia, Hepatic C, High Blood Cholesterol, High Blood Pressure/Heart Disease, HIV, Immune Deficiency, Inflammatory Conditions, Mental/Neurological Disorders, Multiple Sclerosis, Pulmonary Hypertension, and Osteoporosis.



## Freedom Fertility Pharmacy® will offer enhanced support

Infertility affects many individuals. In fact, 1 in 8 couples have trouble getting pregnant or sustaining a pregnancy.<sup>1</sup> Cigna customers who manage the challenges of infertility and other situations where assisted reproductive technology is needed will soon benefit from enhanced support with fertility medication needs.

Starting August 2019, Cigna customers who use Cigna Specialty Pharmacy today will have access to the nation's largest fertility pharmacy, Freedom Fertility Pharmacy (part of Express Scripts' portfolio of services), for support and medication needs.<sup>2,3</sup> These customers will receive a letter notifying them that they can now use Freedom.

Freedom extends many services, ranging from fulfillment of both specialty and non-specialty fertility medications, to personal support from a team of clinicians with extensive fertility-specific experience.

Freedom has helped people with their fertility prescriptions and with managing this unique and highly customized treatment cycle for 25 years. We are proud to offer this support to our Cigna customers.

[Learn More.](#)

1. (2006-2010 National Survey of Family Growth, CDC)

2. Express Scripts prescription volume data, 2018.

3. Infertility coverage is subject to plan terms and conditions and may not be included under all plans. See your plan materials for details.

## Enhanced support with Cigna Collaborative Care® Aligned Pharmacist Program

When it comes to engaging with care partners, there is no one-size-fits-all approach. That's where our Cigna Collaborative Care (CCC) Aligned Pharmacist Program comes in. We align a pharmacist to a CCC point of contact within the collaborative care physician group. The point of contact may be an embedded care coordinator, a nurse case manager, a pharmacist or a quality metric person. The goal is always the same: to provide Cigna patients with consistent, ongoing, personalized pharmacy support.

This work began as a pilot in March of 2015 and has evolved into a pharmacy program strategy to support our CCC partners. We tailor our support to help improve the population's health outcomes and lower medical costs.

### The aligned pharmacist works with the CCC group's point of contact

Aligned pharmacists work for Cigna. Meanwhile, the point of contact works within the CCC group. Together, they identify actionable health care opportunities, based upon shared information and clinical data. On an agreed-upon basis, aligned pharmacists review identified customers' real-time pharmacy claims and benefits. The pharmacists create a report of actionable opportunities to discuss with the point of contact at the CCC. This all works together to support identified customers and help them to reach their best health.

### Program focus includes high-cost, pharmacy-related quality measures:

	Case description	Cigna domain
At-risk / chronic condition population	Diabetes care	HbA1c result value greater than 8.0%
	Coronary artery disease	Patient not taking a statin
	Diabetes mellitus	Patient compliant with prescribed statin

### Results show that positive momentum continues:

<b>25%</b> of those with diabetes and HbA1c over 8.0 moved to the targeted range. <sup>1</sup>	<b>21%</b> of those with coronary artery disease not on a statin began taking one. <sup>1</sup>	<b>58%</b> of customers not adherent to a statin became adherent. <sup>1</sup>
---	--	---

The Cigna Collaborative Care Aligned Pharmacist Program continues to grow, with consistent onboarding of new groups. By end of April 2019, 50 groups were participating in the program.<sup>2</sup>

### Learn more

[Check out our Cigna Collaborative Care Video](#)

1. Cigna Accountable Care quality measurement data. From quarter three 2018.

2. Based on CCC Aligned Pharmacist Program data as of May 2019. Subject to change.



## Drug updates

### Pipeline review

This section highlights some of the pipeline drugs expected to be approved by the U.S. Food and Drug Administration (FDA) in late 2019 or early 2020 that may significantly impact clinical practice and/or pharmaceutical costs.

Drug name/ manufacturer	Proposed use	How it works	What's important
<b>bb2121</b> / bluebird bio	Treatment of advanced multiple myeloma that has failed or not responded to other therapies	bb2121 is a chimeric antigen receptor T-cell therapy (CAR-T) immune-oncology agent. CAR-T therapy is a new type of immuno-oncology <b>that harnesses patient's own immune system to eliminate cancer cells.</b>	<b>Route of administration:</b> IV injection <b>Benefit coverage:</b> Medical <b>Anticipated FDA decision:</b> Early 2020 <b>U.S. sales forecast in 2024:</b> \$378M
<b>luspatercept</b> / Acceleron Pharma, Inc.	Treatment of Beta-Thalassemia, an ultra-rare genetic blood disorder that causes severe anemia	Luspatercept is the first treatment designed to <b>repair the red blood cell (RBC) production defect that causes Beta-Thalassemia and restore RBC production.</b> It works by targeting specific proteins involved in late-stage red blood cell production and significantly reducing or eliminating the need for frequent and lifelong blood transfusions.	<b>Route of administration:</b> Subcutaneous (SC) self-administered injection <b>Benefit coverage:</b> Pharmacy <b>Anticipated FDA decision:</b> 4Q2019 <b>U.S. sales forecast in 2024:</b> \$544M
<b>valoctogene roxaparvovec</b> / BioMarin Pharmaceutical, Inc.	Treatment of hemophilia A	Valoctogene is a one-time gene therapy treatment designed to replace the missing gene that causes hemophilia A, thereby restoring normal blood clotting function and <b>eliminating the need for lifelong factor replacement therapy.</b>	<b>Route of administration:</b> IV injection <b>Benefit coverage:</b> Medical <b>Anticipated FDA decision:</b> Early 2020 <b>U.S. sales forecast in 2024:</b> \$657M
<b>aducanumab</b> / Biogen, Inc.	Treatment and/or prevention of early Alzheimer's Disease	The memory loss and functional decline of Alzheimer's Disease has been linked to the formation of amyloid plaques, abnormal protein deposits that build up in the brain. Aducanumab binds to and may reduce amyloid plaques from the brain, potentially slowing the progress of Alzheimer's Disease. Clinical studies of aducanumab have included individuals between the ages of 50 and 85 with mild to moderate cognitive impairment.	<b>Route of administration:</b> IV injection <b>Benefit coverage:</b> Medical <b>Anticipated FDA decision:</b> 2020 <b>U.S. sales forecast in 2024:</b> \$1.9B

Notes:

U.S. sales forecast provided by EvaluatePharma. [www.evaluatepharma.com](http://www.evaluatepharma.com) Accessed June 17, 2019

Benefit coverage is based on currently available information and could change pending final FDA-approved prescribing information.



## Formulary updates

The following changes were made to Cigna formularies between January 4, 2019 and April 26, 2019.

### Brand drug additions

BRAND NAME	STRENGTH	COMMON USE	CLINICAL EDITS	COPAY TIER				
				Standard formulary	Value formulary	Performance formulary	Advantage formulary	Legacy formulary
AFREZZA	8 UNIT(90)	Diabetes	PA	NC	NC	NC	NC	3
DIVIGEL	0.75/0.75G	Menopause symptoms		2	3	2	3	2
PROMACTA	12.5 MG	Hematologic disorders	PA	3	3	3	3	3
TIROSINT-SOL	13, 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200 MCG/ML	Thyroid replacement		3	3	3	3	3
TREMFYA	100 MG/ML	Psoriasis	PA	3	3	3	3	3
AIMOVIG	70, 140 MG/ML	Migraine	PA	2	2	2	2	2
BALVERSA	3, 4, 5 MG	Bladder cancer	PA	3	3	3	3	3
CABLIVI	11 MG	Hematologic disorders	PA	3	3	3	3	3
DEXCOM G6 SENSOR		Diabetes	PA, QL	2	2	2	2	2
DIACOMIT	250, 500 MG	Seizure disorders		3	3	3	3	3
DOVATO	50MG-300MG	HIV/AIDS		3	3	3	3	3
DXEVO	1.5 MG	Inflammatory conditions		NC	NC	NC	NC	3
FREESTYLE LIBRE 10 DAY SENSOR		Diabetes	PA, QL	2	2	2	2	2
FREESTYLE LIBRE 14 DAY SENSOR		Diabetes	PA, QL	2	2	2	2	2
INGREZZA INITIATION PACK	40 MG-80MG	Movement disorders	PA	3	3	3	3	3
LOTEMAX SM	0.0038%	Ocular pain and inflammation		2	3	2	3	2
MAVENCLAD	10 MG	Multiple sclerosis	PA	3	3	3	3	3
MAYZENT	0.25, 2 MG	Multiple sclerosis	PA	3	3	3	3	3
NIVESTYM	300, 480 MCG	Neutropenia (low white blood cells)	PA	3	3	3	3	3
PROGRAF	0.2, 1 MG	Prevent organ rejection after transplant		3	3	3	3	3
QMIIZ ODT	7.5, 15 MG	Rheumatoid arthritis, osetoarthritis	ST	3	3	3	3	3



## Brand drug additions

BRAND NAME	STRENGTH	COMMON USE	CLINICAL EDITS	COPAY TIER				
				Standard formulary	Value formulary	Performance formulary	Advantage formulary	Legacy formulary
SKYRIZI	75MG/0.83	Psoriasis	PA	3	3	3	3	3
TUXARIN ER	8MG-54.3MG	Cough suppressant	QL	3	3	3	3	3
QMIIZ ODT	15 MG	NSAIDS, cyclooxygenase inhibitor - type analgesics	ST	3	3	3	3	3
SKYRIZI	75MG/0.83	Antipsoriatic agents, systemic	PA	3	3	3	3	3
TUXARIN ER	8MG-54.3MG	Opioid antitussive-1st generation antihistamine	QL	3	3	3	3	3

PA: Prior authorization

T1/Tier 1: Generic

QL: Quantity limit

T2/Tier 2: Brand

ST: Step therapy

T3/Tier 3: Non-preferred

NC: Not covered: This drug is not covered. However, if the covered alternative is not appropriate for the customer, there is a process where his/her provider can request approval of this drug.

## Generic drug additions

GENERIC NAME	STRENGTH	CORRESPONDING BRAND NAME	COMMON USE	CLINICAL EDITS	COPAY TIER				
					Standard formulary	Value formulary	Performance formulary	Advantage formulary	Legacy formulary
ACYCLOVIR CREAM	5%	ZOVIRAX	Herpes simplex infection	QL	NC	NC	NC	NC	1
ALBUTEROL SULFATE	90 MCG	PROAIR HFA	Asthma, COPD		2	NC	2	NC	2
ALBUTEROL SULFATE	90 MCG	VENTOLIN HFA	Asthma, COPD		2	3	2	3	2
ALISKIREN HEMIFUMARATE	150, 300 MG	TEKURNA	Hypertension		1	1	1	1	1
AMBRISENTAN	5, 10 MG	LETAIRIS	Pulmonary arterial hypertension	PA	1	1	1	1	1
BUPRENORPHINE HCL/NALOXONE HCL	2 MG-0.5MG, 4MG-1MG, 12 MG-3 MG	SUBOXONE	Substance abuse disorder		1	1	1	1	1
BENZHYDROCODONE/ACETAMINOPHEN	4.08-325, 6.12-325, 8.16-325 MG	APADAZ	Short-term treatment of moderate-to-severe acute pain	PA	1	1	1	1	1
CHLORZOXAZONE	375,750 MG	LORZONE	Muscle relaxant		NC	NC	NC	NC	1
CINACALCET HCL	30, 60, 90 MG	SENSIPAR	Hyperparathyroidism		1	1	1	1	1
DEFERASIROX	125, 250, 500 MG	EXJADE	Chronic iron overload		1	1	1	1	1
DESFLURANE	100%	SUPRANE	Anesthetic		1	1	1	1	1



Generic drug additions, continued from page 6

## Generic drug additions

GENERIC NAME	STRENGTH	CORRESPONDING BRAND NAME	COMMON USE	CLINICAL EDITS	COPAY TIER				
					Standard formulary	Value formulary	Performance formulary	Advantage formulary	Legacy formulary
DICLOFENAC EPOLAMINE	1.30%	FLECTOR	Inflammatory conditions	QL	1	1	1	1	1
DOXYCYCLINE HYCLATE	80 MG	DOXYCYCLINE	Bacterial infection	ST	NC	NC	NC	NC	1
ERYTHROMYCIN ETHYLSUCCINATE	400MG/5ML	ERYPED 400	Bacterial infection		1	1	1	1	1
ESCITALOPRAM OXALATE	10 MG/10ML	ESCITALOPRAM OXALATE	Depression	QL	1	1	1	1	1
FLUTICASONE/SALMETEROL	100-50, 250-50, 500-50 MCG	ADVAIR DISKUS	Asthma, COPD		1	1	1	1	1
GELATIN SPONGE, ABSORB/PORCINE	100CM, 12-7MM	GELFOAM COMPRESSED	Surgical bleeding		1	1	1	1	1
HALOBETASOL PROPIONATE FOAM	0.05%	LEXETTE	Inflammatory conditions		1	1	1	1	1
HEPARIN SODIUM, PORCINE/PF	5000/0.5ML	HEPARIN SODIUM	Anticoagulant		1	1	1	1	1
LEVORPHANOL TARTRATE	3 MG	LEVORPHANOL TARTRATE	Short-term treatment of moderate-to-severe acute pain	PA	NC	NC	NC	NC	1
MINOCYCLINE HCL	80, 105 MG	SOLODYN	Bacterial infection		1	1	1	1	1
PROMETHAZINE/DEXTROMETHORPHAN	6.25-15/5	PROMETHAZINE-DM	Cough suppressant		1	1	1	1	1
PYRIDOSTIGMINE BROMIDE	60 mg/5 mL	MESTINON	Myasthenia gravis		1	1	1	1	1
RANOLAZINE	500, 1000 MG	RANEXA	Chronic angina	QL	1	1	1	1	1
SEVELAMER HCL	800 MG	RENAGEL	Chronix kidney disease		1	1	1	1	1
SIROLIMUS	1 MG/ML	RAPAMUNE	Prevent organ rejection after transplant		1	1	1	1	1
THEOPHYLLINE ANHYDROUS	80MG/15ML	ELIXOPHYLLIN	Asthma, COPD		1	1	1	1	1



Generic drug additions, continued from page 7

## Generic drug additions

GENERIC NAME	STRENGTH	CORRESPONDING BRAND NAME	COMMON USE	CLINICAL EDITS	COPAY TIER				
					Standard formulary	Value formulary	Performance formulary	Advantage formulary	Legacy formulary
TOREMIFENE CITRATE	60 MG	FARESTON	Breast cancer	QL	1	1	1	1	1
VIGABATRIN	500 MG	SABRIL	Seizure disorders		1	1	1	1	1
THEOPHYLLINE ANHYDROUS	80MG/15ML	ELIXOPHYLLIN	XANTHINES		1	1	1	1	1
TOREMIFENE CITRATE	60 MG	FARESTON	Selective Estrogen Receptor Modulators (SERMS)	QL	1	1	1	1	1
VIGABATRIN	500 MG	SABRIL	Anticonvulsants		1	1	1	1	1

PA: Prior authorization

T1/Tier 1: Generic

QL: Quantity limit

T2/Tier 2: Brand

ST: Step therapy

T3/Tier 3: Non-preferred

NC: Not covered: This drug is not covered. However, if the covered alternative is not appropriate for the customer, there is a process where his/her provider can request approval of this drug.

## Tier changes

BRAND NAME	STRENGTH	COMMON USE	TIER CHANGE	CLINICAL EDITS	PDL TIER				
					Standard formulary	Value formulary	Performance formulary	Advantage formulary	Legacy formulary
AIMOVIG	70 MG/ML AUTOINJECTOR	Migraine	From 3 to 2	PA	2	2	2	2	2
BELBUCA	75, 150, 300, 450, 600, 750, 900 MCG FILM	Moderate-to-severe pain	Remove ST		2	2	2	2	2
CARAFATE	1 GM/10 ML SUSPENSION	Gastro-intestinal ulcer	From 3 to 2		2	2	2	2	
COMBIGEN	0.2%-.05% EYE DROPS	Glaucoma	From 3 to 2		2	2	2	2	2
ESBRIET	267 MG CAPSULE, 801 MG TABLET	Pulmonary fibrosis	From 3 to 2	PA	2	2	2	2	2
FLOVENT, FLOVENT HFA	50, 100, 250 MCG DISKUS; 44, 110, 220 MCG INHALER	Asthma, COPD	From 3 to 2		2	2	2	2	2
LATUDA	20, 40, 60, 80, 120 MG TABLET	Schizophrenia, bipolar disorder	From 3 to 2		2	2	2	2	2
LETAIRIS	5, 10MG TABLET	Pulmonary arterial hypertension	From 3 to 2	PA	2	2	2	2	2





Tier changes, continued from page 8

## Tier changes

BRAND NAME	STRENGTH	COMMON USE	TIER CHANGE	CLINICAL EDITS	PDL TIER				
					Standard formulary	Value formulary	Performance formulary	Advantage formulary	Legacy formulary
LUMIGAN	0.01% EYE DROPS	Glaucoma	From 3 to 2		2	NC (no change)	2	NC (no change)	2
OFEV	100, 150 MG CAPSULE	Pulmonary fibrosis	From 3 to 2	PA	2	2	2	2	2
OPSUMIT	10 MG TABLET	Pulmonary arterial hypertension	From 3 to 2	PA	2	2	2	2	2
SOOLANTRA	1% CREAM	Rosacea	From 3 to 2		2	2	2	2	2
STRENSIQ	18 MG/0.45 ML, 28 MG/0.7 ML, 40 MG/ML AND 80 MG/0.8 ML VIAL	Hypophosphatemia	From 3 to 2	PA	2	2	2	2	2
TOBI PODHALER	28 MG INHALE CAP	Bacterial infection	From 3 to 2		2	2	2	2	2
TRACLEER	32, 62.5, 125 MG TABLET	Pulmonary arterial hypertension	From 3 to 2	PA	2	2	2	2	2
V-GO	20, 30 AND 40 DISPOSABLE DEVICE	Diabetes	From 3 to 2		2	2	2	2	2
XIFAXAN	200, 500 MG TABLET	Bacterial infection	From 3 to 2		2	2	2	2	2
TRACLEER	32 MG TABLET FOR SUSP	Pulmonary Anti-Htn, Endothelin Receptor Antagonist		PA	2	2	2	2	2
V-GO	20, 30 AND 40 DISPOSABLE DEVICE	Diabetic Supplies			2	2	2	2	2
XIFAXAN	200, 500 MG TABLET	Rifamycins and related Derivative Antibiotics			2	2	2	2	2

PA: Prior authorization

T1/Tier 1: Generic

QL: Quantity limit

T2/Tier 2: Brand

ST: Step therapy

T3/Tier 3: Non-preferred

NC: Not covered: This drug is not covered. However, if the covered alternative is not appropriate for the customer, there is a process where his/her provider can request approval of this drug.



## Utilization management changes

BRAND NAME	GENERIC NAME	STRENGTH	UM CHANGE	COMMON USE
BELBUCA	Buprenorphine HCL	75, 150, 300, 450, 600, 750, 900 MCG FILM	ST removed	Moderate-to-severe pain
LATUDA	Lurasidone HCL	20, 40, 60, 80, 120 MG TABLET	ST removed	Schizophrenia, bipolar disorder
RANEXA ER	Ranolazine	500, 1,000 MG TABLET	ST removed	Chronic angina

## On the horizon – upcoming first generic launches\*

TARGET DATE	BRAND NAME	GENERIC NAME	COMMON USE	2017 U.S. BRAND SALES
2H2019	LYRICA (capsules)	Pregabalin	Seizures, neuropathic pain	\$5,465M
2H2019	ULORIC	Febuxostat	Gout	\$578M
2H2019	APRISO	Mesalamine	Inflammatory Bowel Disease (IBD)	\$312M
2H2019	EMEND (injection) (150 mg)	Fosaprepitant Dimeglumine	Nausea or vomiting of chemotherapy	\$328M
2H2019	EVZIO	Naloxone Hydrochloride	Substance dependence or overdose	\$57M
2H2019	ROZEREM	Ramelteon	Insomnia	\$93M
2H2019	TRAVATAN Z	Travoprost	Glaucoma	\$544M
2020	ATRIPLA	Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate	HIV	\$1,273M
2020	TRUVADA (200 mg/300 mg)	Emtricitabine; Tenofovir Disoproxil Fumarate	HIV	\$3,151M
2020	KUVAN (tablet)	Sapropterin Dihydrochloride	Phenylketonuria	\$25M
2020	AFINITOR (10 mg)	Everolimus	Cancer	\$394M
2020	SILENOR	Doxepin Hydrochloride	Insomnia	\$47M
2020	NOXAFIL	Posaconazole	Fungal infections	\$25M
2020	DICLEGIS	Doxylamine Succinate; Pyridoxine Hydrochloride	Nausea and vomiting associated with pregnancy	\$163M
2020	ZORTRESS	Everolimus	Prevent rejection of organ transplant	\$146M

\* Source: IPD Analytics, [www.ipdanalytics.com](http://www.ipdanalytics.com), Accessed June 17, 2019



Health benefit plans vary, but in general to be eligible for coverage a drug must be approved by the Food and Drug Administration (FDA), prescribed by a health care professional, purchased from a licensed pharmacy and medically necessary. Some plans require use of an in-network pharmacy for prescriptions to be covered. Coverage is subject to any plan deductible, copayment and/or coinsurance requirements. Product availability may vary by location and plan type and is subject to change. All group health insurance policies and health benefit plans contain exclusions and limitations. For costs and complete details of prescription drug coverage, contact a Cigna representative.

All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, (CHLIC), Cigna Behavioral Health, Inc., Cigna Health Management, Inc., Accredo Health Group, Inc., Express Scripts, Inc., Tel-Drug, Inc., Drug, Inc., Tel-Drug of Pennsylvania, L.L.C., and HMO or service company subsidiaries of Cigna Health Corporation. "Cigna Home Delivery Pharmacy" refers to Tel-Drug, Inc. and Tel-Drug of Pennsylvania, L.L.C. "Accredo" refers to Accredo Health Group, Inc. "Freedom Fertility Pharmacy" refers to Lynnfield Drug, Inc. Policy forms: OK - HP-APP-1 et al., OR - HP-POL38 02-13, TN - HP-POL43/HC-CER1V1 et al. (CHLIC). The Cigna name, logo, "Together, all the way," "Cigna Pharmacy Management," "myCigna," and "Cigna Collaborative Care" are trademarks of Cigna Intellectual Property, Inc. "Accredo," "Therapeutic Resource Centers," "Express Scripts," and "Freedom Fertility Pharmacy" are trademarks of Express Scripts Strategic Development, Inc. This newsletter is not intended for residents of New Mexico.